As Europe’s leading Pre-Filled Syringes conference, the 2020 event will assess innovations in device engineering and components, enhancement of human factors, and optimizing packaging and ...

PCI Pharma Services is acquiring an entire equity stake in Ajinomoto Althea Inc. (Althea), a U.S.-based sterile fill-finish ...

Argenx’s VYVGART Hytrulo prefilled syringe for self-injection has received FDA approval for the treatment of adult patients with generalized myasthenia gravis.

PCI Pharma Services ("PCI") – a leading global contract development and manufacturing organization (CDMO) focused on ...

Already thriving with a successful launch of infused Vyvgart and its subcutaneous follow-on Vyvgart Hytrulo to the tune of $2 ...

The newly approved prefilled syringe for self-injection of Vyvgart Hytrulo will provide more convenience and flexibility for ...

Acquisition creates a world-class large-scale manufacturing hub in San Diego region with state-of-the-art aseptic facilities ...

The deal for the San Diego hub provides the CDMO with its first-ever North American manufacturing location for prefilled ...

SAE Media Group's 15th Annual Pre-Filled Syringes and Injectable Drug Devices ... Sustainability for Injectable Delivery Devices Primary Packaging Development Connected Drug Delivery Devices ...

From a pharmaceutical perspective, prefilled syringes offer significant advantages in terms of product stability, shelf life, and packaging efficiency. They can be made from glass or polymer ...

The US Food and Drug Administration (FDA) has approved a pre-filled syringe version of argenx’s Vyvgart, giving generalised myasthenia gravis (gMG) and chronic inflammatory demyelinating ...

The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE’s (NASDAQ:ARGX) Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa ...